Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PROCLAIM: A phase 2, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to examine the effects of AC2592 [glucagon-like peptide 1] administered by continuous subcutaneous infusion in subjects with advanced chronic congestive heart failure

Next Previous
X
Search
Trial Profile

PROCLAIM: A phase 2, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to examine the effects of AC2592 [glucagon-like peptide 1] administered by continuous subcutaneous infusion in subjects with advanced chronic congestive heart failure

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glucagon-like peptide-1 (Primary)
  • Indications Chronic heart failure; Heart failure
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms PROCLAIM
  • Sponsors AstraZeneca

    • Most Recent Events

    • 13 Feb 2008 The expected completion date for this trial is now 1 Sep 2006.
    • 26 Dec 2007 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 26 Dec 2007 Status change from in progress to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top